Protagonist Therapeutics filings document formal disclosures for a biopharmaceutical company built around peptide therapeutics. Form 8-K reports furnish quarterly and annual financial results, corporate updates, Regulation FD presentations and material event exhibits tied to pipeline, collaboration and operating developments.
Proxy and annual meeting filings describe board elections, executive compensation votes, auditor ratification, equity incentive plan matters, stockholder voting results and the company's common stock voting structure. These records also frame governance, compensation and capital-related disclosures for Protagonist's Nasdaq-listed Delaware corporation.
PTGX submitted a Form 144 reporting the sale of 15,000 shares via a stock option exercise to be settled for cash on 03/26/2026. The filing lists prior open-market dispositions by Arturo Molina, including 5,000 shares on 01/27/2026 and 13,151 shares on 01/23/2026.
Protagonist Therapeutics director and CEO Dinesh V. Patel reported option exercises, share sales, and a gift of stock. On March 24–25, he exercised stock options covering 54,700 shares of Common Stock at an exercise price of $8.58 per share and acquired the same number of shares.
He then sold 54,700 Common Stock shares in open-market transactions at $101.00 per share. On March 23, he made a bona fide gift of 50,000 Common Stock shares to relatives. Following these transactions, Patel directly holds 524,938 shares of Protagonist Therapeutics Common Stock.
PTGX submitted a Form 144 reporting a proposed sale of 54,700 shares of Common Stock via an option exercise on 03/24/2026, with proceeds to be received in cash. The filing also lists prior open-market dispositions by Dinesh Patel of 19,315 shares on 01/23/2026, 24,890 shares on 01/26/2026, and 4,068 shares on 01/27/2026.
Protagonist Therapeutics outlines a broad late‑ and early‑stage pipeline built on its peptide platform across inflammation, hematology and obesity. Lead asset Icotyde, an oral IL‑23 receptor antagonist licensed to Janssen, has marketing applications filed with the FDA and EMA for moderate‑to‑severe plaque psoriasis, with Janssen guiding to a potential 2026 U.S. launch, subject to approval.
Rusfertide, an injectable hepcidin mimetic for polycythemia vera partnered with Takeda, has an NDA filed in the United States and has Fast Track, Orphan Drug and Breakthrough Therapy designations. Protagonist and Takeda currently share U.S. profits and losses 50/50, and Protagonist expects to exercise a contractual opt‑out in 2026 that would convert this into a global royalty stream.
The company is also advancing PN‑881, an oral IL‑17 antagonist now in Phase 1, an oral hepcidin mimetic PN‑8047, and two obesity candidates, PN‑477 (triple GLP‑1/GIP/glucagon agonist) and PN‑458 (dual GLP‑1/GIP agonist), both with planned oral and injectable formulations. Protagonist ended 2025 with approximately $646.0 million in cash, cash equivalents and marketable securities, up from $559.2 million at year‑end 2024, and remains eligible for substantial future milestones and royalties from its Janssen and Takeda collaborations.
Protagonist Therapeutics reported a challenging 2025 financially but highlighted major regulatory and pipeline milestones. License and collaboration revenue fell to $46.0 million from $434.4 million in 2024, while research and development expense rose to $159.3 million and general and administrative expense to $44.9 million.
The company posted a full-year net loss of $130.1 million, or $2.05 per basic and diluted share, compared with net income of $275.2 million in 2024. In the fourth quarter, net loss was $44.4 million, versus net income of $131.7 million a year earlier.
Strategically, Protagonist submitted an NDA for rusfertide in December 2025 and has an NDA for ICOTYDE™ under FDA review, with a U.S. regulatory decision for ICOTYDE anticipated in 2026. The company expects to opt out of the 50:50 U.S. profit and loss sharing for rusfertide with Takeda during a 90‑day window expected to open in Q2 2026.
Protagonist ended 2025 with cash, cash equivalents and marketable securities of $646.0 million, up from $559.2 million, which it believes will fund operations through at least the end of 2028. The pipeline includes PN‑881, with Phase 1 completion expected by mid‑2026, and several wholly owned preclinical obesity and hepcidin‑focused candidates.
Protagonist Therapeutics (PTGX) director Williams Lewis T reported exercising stock options and selling shares. On February 17, 2026, he exercised 18,000 stock options at a price of $10.84 per share, converting them into 18,000 shares of common stock. The options are fully vested.
That same day, he sold 18,000 common shares in open-market transactions at a weighted average price of $82.42 per share, with individual trade prices ranging from $81.47 to $83.12. After these transactions, he directly holds 7,825 common shares and 6,000 stock options.
PTGX filed a Form 144 notice for a planned sale of 18,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $1,483,495.20 and 62,515,666 shares outstanding. The securities were acquired on February 17, 2026 through a stock option exercise paid in cash on the same date.
RTW Investments, LP and Roderick Wong report beneficial ownership of 5,059,053 shares of Protagonist Therapeutics common stock, representing 8.1% of the class. This percentage is based on 62,515,666 shares outstanding as of October 29, 2025, as disclosed in the company’s Form 10-Q.
The shares are held by RTW-managed funds, with RTW Investments and Dr. Wong sharing voting and dispositive power. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Protagonist Therapeutics.
Wellington Management Group LLP and affiliated entities report beneficial ownership of 3,171,423 shares of Protagonist Therapeutics, Inc. common stock, representing 5.07% of the class as of the event date. The firms report no sole voting or dispositive power over these shares.
They disclose shared voting power over 2,542,632 shares and shared dispositive power over 3,171,423 shares, which are held of record by investment-advisory clients. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Protagonist.
Protagonist Therapeutics director William D. Waddill reported an option exercise and share sale on February 6, 2026. He exercised 20,000 stock options at an exercise price of $8.31 per share and acquired 20,000 common shares.
On the same date, he sold 20,000 common shares at a weighted average price of $83.68 per share, in multiple trades between $83.65 and $83.87. After these transactions, he directly owned 7,825 shares of common stock, and the reported stock options were fully exercised with 0 options remaining.